CME webcourse aims to improve clinical outcomes in hepatocellular carcinoma
To help clinicians ensure optimal outcomes for patients with HCC, Rockpointe, a leading continuing medical education provider, offers a CME webcourse that covers current and emerging treatment options for advanced HCC and offers guidance about how to make patient-personalized treatment decisions and how to manage treatment-emergent adverse events.
Despite advances in treatment options, hepatocellular carcinoma (HCC) is the third-leading cause of cancer death worldwide, with incidence and mortality increasing each year even as the incidence of most cancers is decreasing. Most HCC cases are diagnosed in advanced stages, where potentially curative therapy is ineffective and outcomes are poor. In recent years, several targeted therapies and immunotherapies have emerged that have drastically improved outcomes in advanced HCC.
The treatment of advanced HCC has been transformed by the development of molecularly targeted therapies and monoclonal antibodies directed against inhibitory receptors on immune cells. In many cases, these therapies have provided improved outcomes for patients who have poor prognoses. Hepatocellular Carcinoma: Interpreting the Evidence to Improve Clinical Outcomes will update participants about key concepts of targeted therapy and immunotherapy, current best practices in selection of optimal first- and second-line therapies, and emerging combination approaches.
This free, hour-long online CME webcourse, part of Rockpointe’s Oncology Exchange, is geared toward all members of the multidisciplinary team involved in the management of patients with HCC, including community oncologists, surgeons, interventional radiologists, radiation oncologists, and hepatologists. The program is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine. At its conclusion, participants should be able to:
- Recognize that the mortality rate for HCC patients is excessively high and adjust clinical practice decisions accordingly.
- Evaluate and implement management strategies to include use of newer therapies in HCC patients who would benefit from such agents.
- Translate emerging clinical science to clinical practice in patients with HCC.
- Discuss clinical evidence that supports guideline recommendations for the management of adverse events associated with novel therapies for HCC.
Hepatocellular Carcinoma: Interpreting the Evidence to Improve Clinical Outcomes, which will be available from XXX to XXX, has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Potomac Center for Medical Education (PCME) and Rockpointe. PCME is accredited by the ACCME to provide continuing medical education for physicians. PCME designates this activity for a maximum of 1.0 AMA PRA Category 1 Credit™.
There is no fee for this activity, which is supported by an educational grant from Bayer US. To receive credit, participants must register, view the CME activity in its entirety, and then complete the post-test, with a score of 75% or better, and evaluation. The estimated time for completion of this activity is one hour. To receive a certificate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.
Through effective continuing medical education, Rockpointe strives to improve and advance the quality of patient care. Its educational programs have been at the forefront of new issues in healthcare, such as managing challenges posed by COVID-19, addressing racial disparities in care, and combating the nation’s opioid crisis.
As part of its commitment to quality, Rockpointe works to inform the continuing-education community of significant quality-improvement issues through news and analysis on Policy and Medicine. In addition, its popular Medical Education Exchange (MEDX) CME regional meetings include sessions on the basics of quality improvement and alternative payment models, as well as relevant and scientifically accurate sessions on numerous disease states. All sessions include links back to associated National Quality Priorities to reinforce the bigger picture and the triple aim of: 1) improving health and 2) lowering cost to 3) better the patient experience. At Rockpointe, education equals quality.
For more details and to register for Hepatocellular Carcinoma: Interpreting the Evidence to Improve Clinical Outcomes, click here.
